166 related articles for article (PubMed ID: 14560148)
1. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease.
von Tirpitz C; Epp S; Klaus J; Mason R; Hawa G; Brinskelle-Schmal N; Hofbauer LC; Adler G; Kratzer W; Reinshagen M
Eur J Gastroenterol Hepatol; 2003 Nov; 15(11):1165-70. PubMed ID: 14560148
[TBL] [Abstract][Full Text] [Related]
2. Acute alteration in bone mineral density and biochemical markers for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy.
Fujita T; Satomura A; Hidaka M; Ohsawa I; Endo M; Ohi H
Calcif Tissue Int; 2000 Mar; 66(3):195-9. PubMed ID: 10666494
[TBL] [Abstract][Full Text] [Related]
3. Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis.
Sasaki N; Kusano E; Ando Y; Nemoto J; Iimura O; Ito C; Takeda S; Yano K; Tsuda E; Asano Y
Bone; 2002 Jun; 30(6):853-8. PubMed ID: 12052453
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of bone mineral density, bone turnover markers, the OPG/RANKL system and sTNF-RI in Crohn's disease].
Sánchez Cano D; Ruiz-Villaverde R; Olvera Porcel MC; Callejas Rubio JL; Pérez CC; García MG; Calvin JG; Ortego Centeno N
Gastroenterol Hepatol; 2011 Jan; 34(1):3-9. PubMed ID: 21216496
[TBL] [Abstract][Full Text] [Related]
5. Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG).
Sasaki N; Kusano E; Takahashi H; Ando Y; Yano K; Tsuda E; Asano Y
J Bone Miner Metab; 2005; 23(1):41-7. PubMed ID: 15616893
[TBL] [Abstract][Full Text] [Related]
6. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
[TBL] [Abstract][Full Text] [Related]
7. A single dose of intravenous zoledronate prevents glucocorticoid therapy-associated bone loss in acute flare of Crohn's disease, a randomized controlled trial.
Klaus J; Haenle MM; Schröter C; Adler G; von Boyen G; Reinshagen M; von Tirpitz C
Am J Gastroenterol; 2011 Apr; 106(4):786-93. PubMed ID: 21386830
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis.
Sasaki N; Kusano E; Ando Y; Yano K; Tsuda E; Asano Y
Nephrol Dial Transplant; 2001 Mar; 16(3):479-82. PubMed ID: 11239019
[TBL] [Abstract][Full Text] [Related]
9. Reducing glucocorticoid dosage improves serum osteocalcin in patients with rheumatoid arthritis-results from the TOMORROW study.
Tada M; Inui K; Sugioka Y; Mamoto K; Okano T; Koike T; Nakamura H
Osteoporos Int; 2016 Feb; 27(2):729-35. PubMed ID: 26294294
[TBL] [Abstract][Full Text] [Related]
10. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.
Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R
J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients.
Miheller P; Muzes G; Hritz I; Lakatos G; Pregun I; Lakatos PL; Herszényi L; Tulassay Z
Inflamm Bowel Dis; 2009 Nov; 15(11):1656-62. PubMed ID: 19408329
[TBL] [Abstract][Full Text] [Related]
12. Changes in the serum growth factors and osteoprotegerin after bone marrow transplantation: impact on bone and mineral metabolism.
Baek KH; Lee WY; Oh KW; Kim HS; Han JH; Kang MI; Cha BY; Lee KW; Son HY; Kang SK; Kim CC
J Clin Endocrinol Metab; 2004 Mar; 89(3):1246-54. PubMed ID: 15001618
[TBL] [Abstract][Full Text] [Related]
13. Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn's disease.
Turk N; Cukovic-Cavka S; Korsic M; Turk Z; Vucelic B
Eur J Gastroenterol Hepatol; 2009 Feb; 21(2):159-66. PubMed ID: 19098682
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis.
Franck H; Meurer T; Hofbauer LC
J Rheumatol; 2004 Nov; 31(11):2236-41. PubMed ID: 15517638
[TBL] [Abstract][Full Text] [Related]
15. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.
Voskaridou E; Terpos E; Spina G; Palermos J; Rahemtulla A; Loutradi A; Loukopoulos D
Br J Haematol; 2003 Nov; 123(4):730-7. PubMed ID: 14616979
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption.
Nakamura M; Udagawa N; Matsuura S; Mogi M; Nakamura H; Horiuchi H; Saito N; Hiraoka BY; Kobayashi Y; Takaoka K; Ozawa H; Miyazawa H; Takahashi N
Endocrinology; 2003 Dec; 144(12):5441-9. PubMed ID: 14500574
[TBL] [Abstract][Full Text] [Related]
17. The role of serum osteoprotegerin and receptor-activator of nuclear factor-κB ligand in metabolic bone disease of women after obesity surgery.
Balsa JA; Lafuente C; Gómez-Martín JM; Galindo J; Peromingo R; García-Moreno F; Rodriguez-Velasco G; Martínez-Botas J; Gómez-Coronado D; Escobar-Morreale HF; Botella-Carretero JI
J Bone Miner Metab; 2016 Nov; 34(6):655-661. PubMed ID: 26438320
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
Swanson C; Lorentzon M; Conaway HH; Lerner UH
Endocrinology; 2006 Jul; 147(7):3613-22. PubMed ID: 16614077
[TBL] [Abstract][Full Text] [Related]
19. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
20. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis.
Ardizzone S; Bollani S; Bettica P; Bevilacqua M; Molteni P; Bianchi Porro G
J Intern Med; 2000 Jan; 247(1):63-70. PubMed ID: 10672132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
